Vaxxinity announced the publication of groundbreaking data in Nature Medicine from its Phase 1 trial of UB-312, which targets Parkinson's disease (PD). This is the first PD candidate to show reduced pathology via a seed amplification assay and suggest clinical improvement in motor experiences. The trial, involving 20 early PD patients, indicated successful target engagement and immunogenicity. UB-312 induced antibodies significantly decreased aggregated α-synuclein levels, suggesting potential disease-modifying effects. The trial, funded by The Michael J. Fox Foundation, met its primary outcomes, demonstrating UB-312's good tolerance and efficacy in inducing anti-αSyn antibodies in PD patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.